

Prof. Dr. med. Bodo Plachter

*16.11.1957

Univ.-Professor of Virology, **C3**
Deputy Director of the Institute for Virology

Institute for Virology
University Medical Center of the Johannes Gutenberg University Mainz
D-55131 Mainz, Obere Zahlbacher Str. 67
Tel: +49-6131-179232, Fax: +49-6131-179038
plachter@uni-mainz.de
www.unimedizin-mainz.de/virologie/research/research-groups/ag-plachter.html



Academia

- 1977-1983 Studies in medicine, Friedrich-Alexander University Erlangen-Nürnberg
- 1983 State examination and approbation as physician
- 1986 Doctorate (Dr. med.), Friedrich-Alexander University Erlangen-Nürnberg
- 1993 Habilitation in virology, Friedrich-Alexander University Erlangen-Nürnberg

Career

- Jan. 1984 – Jan. 1986 Research Associate, Institute for Clinical Virology, Friedrich-Alexander University Erlangen-Nürnberg
- Feb. 1986 – Feb. 1987 Assistant at the central institute of the German Army, Koblenz, Department of Medical Microbiology
- Mar. 1987 – Oct. 1988 Research Associate, Institut for Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg
- Nov. 1988 Appointment to the temporary academic council
- Mar. 1993 Appointment to the temporary senior academic council
- Mar. 1993 Venia legendi for virology
- Aug. 1995 Appointment to the C3 professorship of virology, Johannes Gutenberg University Mainz
- Mar. 1996 Univ.-Prof. (C3) of virology, Institute for Virology, Johannes Gutenberg University Mainz
- May 1996 Recognition as Doctor of Microbiology and Infectious Epidemiology

Selected Publications

Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E, Porgador A, Honigman A, **Plachter B**, Mevorach D, Wolf DG, Mandelboim O. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. *Nat Immunol.* 2005. 6: 515-23.

Becke S, Aue S, Thomas D, Schader S, Podlech J, Bopp T, Sedmak T, Wolfrum U, **Plachter B**, Reyda S. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. *Vaccine* 2010. 28: 6191-8.

Becke S, Fabre-Mersseman V, Aue S, Auerochs S, Sedmak T, Wolfrum U, Strand D, Marschall M, **Plachter B**, Reyda S. Modification of the major tegument protein pp65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells. *J Gen Virol.* 2010. 91: 2531-41.

Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, **Plachter B**. Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. *J Gen Virol.* 2007. 88:1429-39.

Besold K, Wills M, **Plachter B**. Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition. *Virology.* 2009. 391: 5-19.

Frankenberg N, Pepperl-Klindworth S, Meyer RG, **Plachter B**. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. *Virology.* 2002. 295:208-16.

Gilbert MJ, Riddell SR, **Plachter B**, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. *Nature* 1996. 383: 720-2.

Grefte JM, van-der-Gun BT, Schmolke S, van-der-Giessen M, van-Son WJ, **Plachter B**, Jahn G, The TH. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. *J Gen Virol.* 1992. 73: 2923-32.

Mersseman V, Besold K, Reddehase MJ, Wolfrum U, Strand D, **Plachter B**, Reyda S. Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies. *J Gen Virol.* 2008. 89: 369-79.